Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AIDS Patent Pool Garners Support From Industry, But Pharma Companies Want Flexibility In Pricing Between Countries

Executive Summary

The drug purchasing group UNITAID may succeed in getting pharmaceutical companies to pool patents on their AIDS medicines. So far, it has won buy-in of the idea from three: Gilead Sciences, Merck and Johnson & Johnson subsidiary Tibotec

You may also be interested in...



Gilead Is First Splash In HIV Patent Pool; Five Other Firms In Negotiations

Gilead's deal with the Medicines Patent Pool limits the developing countries that have access to generics and requires that the drugs be manufactured in India.

WHO Report Evaluates Ways To Fund Drug R&D For Developing Countries; Critics Say It Fails To Address Access To Medicines

How can governments and industry boost research and development on diseases prevalent in developing countries

WHO Report Evaluates Ways To Fund Drug R&D For Developing Countries; Critics Say It Fails To Address Access To Medicines

How can governments and industry boost research and development on diseases prevalent in developing countries

Related Content

Topics

UsernamePublicRestriction

Register

PS051773

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel